Core Insights - Investment strategist Shay Boloor has identified ten sub-$10 billion market-cap companies poised to benefit from long-term trends leading into 2026, focusing on essential platforms and hard infrastructure rather than short-term narratives [1][19] Company Summaries - **Ondas Holdings (NASDAQ: ONDS)**: Developing a wireless connectivity layer for industrial and autonomous drones, with strong revenue growth momentum and a year-to-date stock increase of over 230% [2][3] - **Cipher Mining (NASDAQ: CIFR)**: Transitioning to a digital infrastructure owner with large-scale power and data-center assets, stock up over 250% year to date [6] - **Jumia Technologies (NYSE: JMIA)**: Refining its e-commerce and logistics model in Africa, with improved order volumes and a stock gain of about 215% [7] - **DigitalOcean Holdings (NYSE: DOCN)**: Regaining investor confidence with strong earnings and positioning as an AI inference cloud, stock up 40% year to date [8] - **IREN Limited (NASDAQ: IREN)**: Expanding compute capacity with record profitability and a nearly 285% stock increase [9] - **ClearPoint Neuro (NASDAQ: CLPT)**: Advancing image-guided navigation platforms for neurosurgeons, with a stock decrease of 18% year to date [10] - **Eos Energy Enterprises (NASDAQ: EOSE)**: Developing zinc-based energy storage systems for high-load environments, stock up 170% year to date [11] - **Navitas Semiconductor (NASDAQ: NVTS)**: Supplies gallium nitride power chips for AI data centers, stock up 145% year to date despite near-term pressures [14] - **Viking Therapeutics (NASDAQ: VKTX)**: Developing GLP-1 therapies for obesity and diabetes, with a stock decrease of about 10% [16] - **TransMedics Group (NASDAQ: TMDX)**: Scaling its organ care system with a focus on logistics, stock up about 90% [18]

Core Viewpoint - The article discusses the current landscape of heavily shorted stocks, highlighting the reasons traders engage in short selling and the potential for short squeezes as investment opportunities [2][3][4]. Summary by Sections Heavily Shorted Stocks - Stocks become heavily shorted when experienced traders and institutional investors believe the company is fundamentally overvalued, anticipating a price decline [2]. - Short sellers borrow shares, sell them at high prices, and aim to repurchase them at lower prices for profit, indicating a strong conviction about the company's risks [3]. Current Market Data - As of December 10, 2025, the top 10 most shorted stocks with market caps above $2 billion and free floats above 5 million are listed, ranked by short interest percentage [5]. - The most heavily shorted stock is Lucid Group, Inc. (NASDAQ: LCID) with a short interest of 52.70%, followed by Avis Budget Group, Inc. (NASDAQ: CAR) at 51.53% and Choice Hotels International, Inc. (NYSE: CHH) at 49.05% [6][7]. Market Characteristics - Heavily shorted stocks often reflect a battleground between negative fundamentals and speculative trading, where short squeezes can lead to significant, rapid gains but also come with high risk and volatility [8]. - Monitoring short interest can help identify potential short squeeze candidates, although timing such trades is challenging [8].

These companies are worth your attention.Looking for stocks with explosive growth potential? Look no further than TransMedics Group (TMDX 1.32%) and Abivax Société Anonyme (ABVX +6.94%). Both healthcare specialists have seen their shares jump significantly this year already.However, there could be plenty more upside on the way for these little-known stocks. Here's why TransMedics Group and Abivax might be worth considering, especially for investors with an elevated risk tolerance.1. TransMedics GroupTransMe ...

We came across a bullish thesis on TransMedics Group, Inc. on Make Money, Make Time’s Substack by Oliver | MMMT Wealth. In this article, we will summarize the bulls’ thesis on TMDX. TransMedics Group, Inc.'s share was trading at $150.42 as of December 1st. TMDX’s trailing and forward P/E were 57.60 and 60.98 respectively according to Yahoo Finance. hywards/Shutterstock.com TransMedics Group, Inc. reported Q3 2025 results on October 29th, triggering volatile trading as shares initially fell ~15% after ho ...

A TransMedics executive trimmed his position by $540,300. Director Edward Basile executed an exercise of 4,142 options with immediate sale of all resulting shares in TransMedics Group (TMDX +0.18%) on October 29, 2025, as disclosed in the SEC Form 4 filing.Transaction summaryMetricValueShares sold4,142Transaction value~$540,300Post-transaction shares2,866Post-transaction value (direct ownership)~$385,000Transaction value is based on the SEC Form 4 weighted average purchase price of $130.45 as of October 29, ...

TransMedics Group (NasdaqGM:TMDX) FY Conference December 02, 2025 09:30 AM ET Company ParticipantsGerardo Hernandez - CFOWaleed Hassanein - CEOMike Carrel - CEOConference Call ParticipantsMatt O'Brien - Medtech AnalystMatt O'BrienAll right. Good morning. Thanks so much for joining us. My name's Matt O'Brien. I'm one of the med tech analysts here at Piper. Extremely fortunate to have the TransMedics team here with us today. From the company we have Waleed, who is the CEO of the company, and then Gerardo, who ...

Group 1: MercadoLibre - MercadoLibre is the leading player in the Latin American e-commerce and fintech markets, with a compound annual growth rate exceeding 30% over the past five and ten years [2] - The stock has recently declined approximately 20% from its all-time high due to increased competition from Amazon in Latin America [3] - E-commerce penetration in Latin America is still in the mid-teens as a percentage of total retail sales, indicating significant growth potential [5] Group 2: TransMedics Group - TransMedics Group is innovating the organ transplantation market with its Organ Care System (OCS), which keeps donor organs alive during transport, addressing issues associated with traditional cold storage methods [6][7] - OCS technology allows for over 80% of donor hearts and lungs to be usable, significantly increasing transplant rates compared to cold storage [9] - The company is expanding into Italy in 2026 and developing a version of OCS for kidneys, which could transform the kidney transplant landscape [11] Group 3: Vertex Pharmaceuticals - Vertex Pharmaceuticals holds a dominant position in the cystic fibrosis market with the only approved therapies targeting the disease's underlying cause [12] - The company is also exploring opportunities in other therapeutic areas, including a non-opioid pain drug that is expected to be a blockbuster [13] - Vertex is advancing its pipeline with plans for regulatory submissions for treatments targeting IgA nephropathy and severe Type 1 diabetes, which could address significant patient populations [15][16]

Core Insights - The article reflects on the importance of learning from past investment decisions, highlighting two stocks that have provided valuable lessons and solid returns [1][2] Group 1: Amazon Case Study - Amazon's Fire Phone was a significant misstep, leading to the decision to sell the stock despite its previous strong performance [3][4] - The stock, which had nearly tripled in value, ultimately became a 14-bagger, demonstrating the importance of long-term thinking and trust in management [4][6] - Key lessons learned include avoiding short-term thinking, trusting founder-led management, and not betting against innovation [6][7] Group 2: TransMedics Group Analysis - TransMedics Group, a provider of Organ Care Systems, was purchased at the beginning of 2023 and initially saw gains before a significant drop in share price following an acquisition announcement [9][10] - Despite initial concerns about the acquisition of Summit Aviation impacting margins, the company’s stock has since tripled from its lows, with sales more than doubling [12][14] - Recent financial performance includes a 32% increase in transplant revenue and a 35% rise in logistics revenue, with a net profit margin of 17% [16] - TransMedics aims to expand its transplant operations significantly and enter new markets, which could provide substantial growth opportunities [16][17]

Group 1 - TransMedics (TMDX) has reached a significant support level and shows potential as a good investment from a technical perspective, having recently broken through the 50-day moving average, indicating a short-term bullish trend [1] - Over the past four weeks, TMDX has gained 11.7%, and it is currently ranked a Zacks Rank 3 (Hold), suggesting the stock could continue to rise [2] - Positive earnings estimate revisions further strengthen the bullish case for TMDX, with no estimates decreasing in the past two months and six estimates increasing, alongside a rise in the consensus estimate [3]

Core Insights - U.S. stocks exhibited mixed performance, with the Nasdaq Composite increasing by over 100 points on Wednesday [1] - Dycom Industries, Inc. reported record third-quarter results, raised its outlook, and announced a significant acquisition [1] Company Performance - Dycom Industries' contract revenues rose by 14.1% year-over-year to $1.45 billion, surpassing analyst expectations of $1.41 billion [1] - The adjusted EPS for Dycom Industries was $3.63, exceeding analyst estimates of $3.20 [1] - Dycom Industries shares increased by 8.1% to $320.17 on Wednesday following the positive results [2] Other Notable Stock Movements - PACS Group, Inc. shares increased by 11.1% to $16.03 [4] - TransMedics Group, Inc. saw a rise of 10.4% to $129.27 [4] - MP Materials Corp. shares jumped by 9.3% to $63.95 after Goldman Sachs initiated coverage with a Buy rating and a $77 price target [4] - BellRing Brands, Inc. surged by 9.1% to $28.64 despite mixed fourth-quarter financial results and FY26 sales guidance below estimates [4] - Hinge Health, Inc. gained 8.2% to $43.93, announcing a $250 million share repurchase program [4] - Kyivstar Group Ltd. rose by 7.6% to $12.06 [4] - Lumentum Holdings Inc. increased by 7.2% to $265.33 after Mizuho Securities initiated coverage with an Outperform rating and a price target of $290 [4]